Binding enhancement by tertiary interactions is a strategy that takes advantage of the higher order folding of functionally important RNAs to bind short nucleic acid-based compounds tightly and more specifically than possible by simple base pairing. For example, tertiary interactions enhance binding of specific hexamers to a group I intron ribozyme from the opportunistic pathogen Pneumocystis carinii by 1,000-to 100,000-fold relative to binding by only base pairing. One such hexamer, d(AnTnGnAnCn)rU, contains an N3 3 P5 phosphoramidate deoxysugar-phosphate backbone (n) that is resistant to chemical and enzymatic decay. Here, it is shown that this hexamer is also a suicide inhibitor of the intron's self-splicing reaction in vitro. The hexamer is ligated in trans to the 3 exon of the precursor, producing dead-end products. At 4 mM Mg 2؉ , the fraction of trans-spliced product is greater than normally spliced product at hexamer concentrations as low as 200 nM. This provides an additional level of specificity for compounds that can exploit the catalytic potential of complexes with RNA targets.Most human therapeutics have been discovered by screening natural products. Synthetic organic chemistry has made it possible to synthesize such natural products and derivatives thereof in large quantities, thus broadening the range of compounds that can be used clinically (1-3). Synthetic methodology coupled with the outpouring of protein structural information has also allowed rational design of completely new therapeutic compounds (4,5). Similarly, the recent explosion in nucleic acid sequence information is providing a knowledge base for structure-based targeting of RNA. The first generation of such therapeutics consists of antisense nucleic acids that bind mRNA through Watson-Crick base pairing and thereby regulate translation (6, 7). Because of the long sequences employed, typically 15-20 nucleotides, potential disadvantages include high cost of synthesis (8) and lack of specificity (9). Cost of synthesis can be reduced and specificity increased by designing short antisense agents whose binding to RNA targets is enhanced by tertiary interactions (10, 11). Here we show that one such hexanucleotide can also be a suicide inhibitor (12, 13) of RNA function. This provides an additional design principle for increasing specificity of compounds that can exploit the catalytic potential of complexes with RNA targets.Our model system is a large-subunit ribosomal RNA (rRNA) precursor from the opportunistic pathogen Pneumocystis carinii, which is a common cause of death in immunocompromised patients (14, 15). The rRNA precursor contains a group I self-splicing intron (10, 16) that provides a potential therapeutic target (16, 17) because self-splicing is required for assembly of active ribosomes (18). Hexamers that mimic this intron's 5Ј exon can bind to the catalytic core of a ribozyme derived from the intron as much as 100,000-fold more tightly than expected if the hexamers bound by simple base pairing (10). Much of this bindi...